Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 10/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.48 |
| ▸ | KDM5A | P29375 | 10/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | KDM5C | P41229 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14413590 | 0.89 | CHEK1 (0.61) | CHEK1CCNA2CDK2CCNA1KDM5A | |
| SCHEMBL14050794 | 0.88 | CHEK1 (0.45) | CHEK1CCNA2CDK2CCNA1KDM5A | |
| SCHEMBL11931345 | 0.83 | CHEK1 (0.47) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL14413501 | 0.82 | CHEK1 (0.41) | CHEK1CCNA2CDK2CCNA1KDM5A | |
| SCHEMBL14050946 | 0.78 | CHEK1 (0.57) | CHEK1CCNA2CDK2CCNA1KDM5A | |
| SCHEMBL14542883 | 0.77 | CHEK1 (0.78) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL14413629 | 0.76 | CHEK1 (0.64) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL14418713 | 0.75 | IRAK1 (0.39) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL11931540 | 0.73 | CHEK1 (0.58) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL11931271 | 0.73 | CHEK1 (0.58) | CHEK1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586576-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8580782-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-09-27 | — | — | US | disclosed |
| US-7196078-B2 | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPOARTION (US) | 2007-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | CHEK1 58/4885CCNA2 29/4885CDK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.